Press Releases

Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply

Revolutionary hemostatic gel for veterinarians now available through Penn Vet  NEW YORK (August 22, 2023) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an …

Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply Read More »

Cresilon's engineer in the Brooklyn biomanufacture

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology

June 29, 2023, New York – Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for Cresilon Hemostatic Gel™ (“CHG™”). This marks Cresilon’s first FDA clearance for human use, validating its revolutionary hemostatic gel …

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology Read More »

Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market

NEW YORK, Oct. 27, 2022 — Cresilon, Inc., the Brooklyn-based biotechnology company developing and manufacturing innovative hemostatic medical device technologies, today announced the successful completion of a $25 million Series A-4 financing round. The financing will support the company’s efforts to aggressively accelerate its global expansion plan and bring its revolutionary hemostatic gel to the human …

Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market Read More »

VETIGEL syringe

Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries

NEW YORK, Sept. 27, 2022 — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, has entered into a Cooperative Research and Development Agreement (“CRADA”) with Walter Reed Army Institute of Research (“WRAIR”), the largest biomedical research facility administered by the U.S. Department of Defense (“DoD”), to advance the development of medical …

Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries Read More »

CHG Cresilon Hemostatic Gel Logo

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology

NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market. …

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology Read More »

Cresilon's GMP manufacturing facility in Brooklyn, NY

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel

NEW YORK, April 8, 2021 – Cresilon, Inc., the Brooklyn-based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million. This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL®, its revolutionary hemostatic gel for the animal health market. It …

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel Read More »